Startseite>>Signaling Pathways>> Microbiology & Virology>> Parasite>>PI-55

PI-55

Katalog-Nr.GC63299

PI-55 ist ein spezifischer Cytokinin-Rezeptor-Inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

PI-55 Chemische Struktur

Cas No.: 1122579-42-3

Größe Preis Lagerbestand Menge
5 mg
316,00 $
Auf Lager
10 mg
513,00 $
Auf Lager
25 mg
1.035,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PI-55 is a specific cytokinin receptor inhibitor. PI-55 is structurally related to 6-benzylaminopurine (BAP) and was shown to inhibit competitively BAP binding on Arabidopsis-specific receptors CRE1/AHK4 and AHK3. PI-55 inhibits cytokinins induced haustorium formation and increased parasite aggressiveness[1].

PI-55 at high concentrations (10 μM and 100 μM), which causes an incomplete blocking of early haustorial structure development, especially when cytokinin activity promotes it. PI-55 treatment also reduces the overall aggressiveness of P. ramosa when applied with BAP in comparison with BAP alone, suggesting that the signaling pathway leading to early haustorial structure formation involves histidine kinase receptors homologous to CRE1/AHK4 and AHK3[1].

[1]. Goyet V, et al. Haustorium initiation in the obligate parasitic plant Phelipanche ramosa involves a host-exudated cytokinin signal. J Exp Bot. 2017;68(20):5539-5552.

Bewertungen

Review for PI-55

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PI-55

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.